Lilly Announces Senior Leadership Appointments
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowEli Lilly and Co. has made a number of leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018.
Josh Smiley has been promoted to senior vice president and chief financial officer. Lilly announced in June that Derica Rice, Lilly’s current CFO, would retire at year-end.
Dan Skovronsky has been promoted to senior vice president for science and technology and president of Lilly Research Labs.
Also, Myles O’Neill has been promoted to senior vice president and president of manufacturing operations. They will all become a member of Lilly’s executive committee.
Aarti Shah, senior vice president and chief information officer, has been named an executive officer. Positioning the information technology function as a direct report to the CEO is critical given the role digital technology and analytics will play in the future of healthcare.
Maria Crowe (pictured), president of manufacturing operations, will retire in December after 35 years of service. She joined Lilly in 1982 and since 2012 has led the company’s global manufacturing network of 14 sites on four continents. Previously, Crowe served as senior vice president global drug product manufacturing, which included emerging markets manufacturing, drug product operations and U.S. distribution. She also served as vice president for drug product manufacturing in the U.S. and Latin America; general manager of Lilly del Caribe in Puerto Rico and general manager of Lilly’s plant in Kinsale, Ireland.
Jan Lundberg (pictured), executive vice president for science and technology and president of Lilly Research Labs, will retire at the end of May 2018 after eight years with Lilly. Prior to joining Lilly he served for 10 years as global head of discovery research at AstraZeneca. Lundberg’s tenure marks a period of tremendous R&D output with Lilly poised to launch as many as 20 new medicines in 10 years. The company improved late-stage success rates and shortened the clinical development timelines under Lundberg’s leadership.